Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stomach Cancer | Preclinical | US | 30 Jan 2022 | |
Stomach Cancer | Preclinical | CN | 30 Jan 2022 | |
Triple Negative Breast Cancer | Preclinical | US | 23 Aug 2021 | |
Triple Negative Breast Cancer | Preclinical | CN | 23 Aug 2021 |